Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A self-guided skills program that teaches new ways to think and act around pain helped people with long-lasting pain; after a clot was removed from a brain artery, an added anti-clot medicine helped more stroke patients recover; a pill form of ketamine helped some people with depression that had not improved with other treatments; a special light-based scan helped tell if donor livers were healthy enough for transplant; a new pill for heart failure looked safe over 28 days and showed early signs it may improve heart function

Good news: People with long-lasting pain improved with a self-guided skills program that teaches new ways to think and act around pain. This could make helpful pain care easier to get when clinics are full or far away.

Self-Directed vs Clinician-Delivered CBT for Chronic Pain

Market readiness: 🙂🙂🙂🙂🙂 (The treatment is already available now (self-guided and clinician-led CBT programs exist); what’s needed is rollout—training, reimbursement, and choosing the best format for different patients.)

Good news: In people who had a clot removed from a brain artery, adding an anti-clot medicine afterward improved recovery in this randomized trial. If confirmed, hospitals could add this step to help more stroke patients get back to independent living.

Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial

Market readiness: 🙂🙂🙂🙂 (The drug is already on the market in many places, but this exact post–clot-removal use still needs more confirmation, safety checks in broader groups, and guideline updates before it becomes standard care.)

Good news: An oral form of ketamine helped some people with hard-to-treat depression in this study. A pill could make ketamine care easier to deliver than clinic-only options, if safety and benefits hold up in larger trials.

Oral Ketamine for Treatment Resistant-Depression

Market readiness: 🙂🙂🙂🙂 (Ketamine is already used in specialty care, but swallowing it for this purpose still needs larger, longer studies (especially on side effects and misuse risk) and clearer dosing standards before routine use.)

Good news: A special light-based scan helped check whether donor livers were healthy enough for transplant. Better “yes or no” decisions could mean more safe transplants and fewer organs wasted.

Human donor liver viability evaluation with polarization-sensitive optical coherence tomography

Market readiness: 🙂🙂🙂 (This looks promising but still needs larger multicenter testing, clear cutoffs that surgeons can trust, and regulatory steps for a clinical device workflow before widespread hospital use.)

Good news: A new pill aimed at helping the heart pump better looked safe and well tolerated over 28 days in people with heart failure. Early signs suggest it may improve heart function, which supports bigger trials.

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

Market readiness: 🙂🙂 (This is an early-stage human trial; it needs larger and longer studies to prove it truly helps people feel better and live longer, and to confirm safety before late-stage trials and approval.)

Thank you for taking the time to take care of yourself and your loved ones.